Strategic collaborations Epigen operates as an incubator that partners with academic groups and provides strategic project management and medicinal chemistry support, enabling collaboration-driven asset development and potential co-development or licensing opportunities with pharma partners.

Clinical readiness timeline Assets are targeted to progress from IP to IND enablement within 2-4 years and reach Phase 1, creating a clear pathway for sale or partnership with large pharma companies seeking expedited early clinical assets.

Externalized expertise A lean model with access to a complete team of experts and resources through collaborations offers cost-efficient asset development, presenting a compelling value proposition for partners looking to de-risk early drug discovery investments.

Strategic partnerships Existing collaboration with Novo Nordisk on the LPA1 receptor antagonist demonstrates credibility and a potential entry point for BD conversations around metabolic, diabetic, and chronic kidney disease programs.

Growth signals Revenue in the small-scale range and the focus on IP-rich, high-potential assets position Epigen as a potential target for licensing deals, co-development agreements, or strategic partnerships with mid-to-large biopharma seeking novel leads with established collaboration history.